Detail akcie NanoViricides Rg online

Business Summary: NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
Financial Summary: BRIEF: For the three months ended 30 September 2025, NanoViricides, Inc revenues was not reported. Net loss decreased 43% to $1.8M. Lower net loss reflects Pharmaceutical Preparations segment loss decrease of 43% to $1.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.23 to -$0.10.